Phase 1 clinical trial results of TIL adoptive cell therapy combined with Nivolumab (NCT03215810) show that among 13 patients, 3 confirmed responses, 11 have reduced tumor burden, including 2 who achieved complete remission after 1.5 years, effectively preventing subsequent relapse associated with PD-L1 expression [439]. Here, CD274 is linked to neoplasm.